+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

Access Advocate for Clinical Research Participation

Fox (Michael J.) Foundation for Parkinson's Research

This program will support implementation and evaluation of a Parkinson’s disease (PD) focused Access Advocate model designed to increase inclusive research participation. Funding will support Access Advocates at clinical sites to build practical, relationship based pathways to improving representative research enrollment and retention.

Important notice: MJFF will be conducting two Q&A sessions to answer any questions related to the RFA on:

Monday, May 11 at 1:00 p.m. US ET

Friday, May 15 at 2:00 p.m. US ET

AI Based Application Success Predictor

1. Focus Directly on Parkinson’s Disease — From Mechanism to Patient Impact

MJFF funds research across basic, translational, and clinical domains.

Proposals must have clear relevance to PD: whether exploring pathogenesis, biomarkers, symptomatic treatments, disease-modifying strategies, neuroprotection, progression, or quality of life.

Both academia and industry are eligible — including small biotech, major pharma, and allied-care professionals.

Predictor: Direct PD relevance, and a transparent path to improve lives of people with Parkinson’s, ranks highly.

2. Strong Therapeutic or Translational Rationale (for Pipeline / Therapeutic Grants)

For therapeutic development grants (e.g., under MJFF’s “Parkinson’s Disease Therapeutics Pipeline Program”), priority is given to projects with strong therapeutic rationale, patient value, and clear preclinical-to-clinical translation potential.

MJFF has funded both small labs and industry — indicating openness to novel ideas whether early stage or more developed.

Predictor: If you propose a therapy — small molecule, biologic, device, biomarker-guided — ensure solid rationale and translational feasibility (e.g. dosing strategy, safety plan, clinically relevant endpoints).

3. Innovative and Ambitious Ideas — Including Novel Mechanisms or Biomarkers

MJFF states that no idea is “too novel” — they are open to bold, out-of-the-box thinking.

Their funding portfolio spans many types of research: biology, biomarkers, digital health, gait and motor symptoms, progression markers, non-motor symptoms.

Predictor: Novelty counts — especially for underexplored areas (biomarkers, non-motor symptoms, digital health, gait/balance, disease trajectory) or unconventional therapeutic paths.

4. Use of Appropriate Models, Data, or Cohorts — Including Access to Existing MJFF Resources

MJFF also funds research-enabling resources, not just hypothesis-driven studies. For example, tools, biomarkers, data sets, digital-health monitoring.

They encourage data/resource sharing, collaborations, and linking with consortiums for broader impact.

Predictor: Leveraging existing cohorts, biospecimens, or being ready to use shared resources (or create broadly usable tools) helps your application.

5. Clear, Feasible Study Design — With Defined Milestones and Translational Path

Especially for preclinical-to-clinical pipeline grants, reviewers look for realistic milestones that can move the project forward.

For clinical or biomarker research: robust methodology, clear endpoints, risk/benefit considerations, and patient value.

Predictor: A tightly scoped plan (2–4 aims), clear milestones, and realistic path to next phases increase chances of funding.

6. Investigator & Team Breadth — Academia + Industry + Multi-Disciplinary Collaboration

MJFF funds both academic researchers and industry/biotech clients — and often encourages public–private collaboration.

Their “Partnering Program” fosters collaboration to accelerate therapeutic development.

Predictor: A team combining basic scientists, clinicians, drug-development experts or tech developers — especially with collaborative or cross-disciplinary strength — is often viewed favorably.

7. Clear Benefit for Patients & Impact on Quality of Life or Disease Course

MJFF funds research spanning symptom management, motor and non-motor symptoms (gait, balance, cognition), biomarker studies, and disease-modification approaches.

They invest heavily — in 2025 alone, they awarded nearly $50 M across 70 grants — indicating high capacity and ambition.

Predictor: Projects that clearly articulate “how this helps people with Parkinson’s now or soon” — not just academic interest — tend to score better.

8. Commitment to Open Data, Sharing, and Consortium Participation

MJFF often supports consortia, shared data sets, collaborative resources, and open partnership models — acknowledging that PD research benefits from data sharing and community effort.

For example, biomarker and molecular-dataset initiatives recently funded involve large-scale resource generation for the community.

Predictor: If your proposal includes data sharing, resource generation, or network-building — this enhances value-for-money for MJFF and increases competitiveness.

9. Administrative Compliance & Principal Investigator as Primary Applicant

MJFF requires that the Principal Investigator (PI) be the main applicant. No co-PIs or paid collaborators listed as primary — ensures accountability and clarity.

Budget overlap with other active grants is prohibited: MJFF funding expects exclusivity for the proposed project.

Predictor: Clean, compliant applications with a single PI and no overlapping funding are far more likely to pass administrative screening.

🎯 What This Means — If You Plan to Apply to MJFF

If you’re preparing a MJFF proposal, aim to:

Tie your work directly to Parkinson’s disease, with a clear impact on biology, diagnostics, therapy, or patient quality-of-life.

For therapeutic or translational proposals — highlight a strong preclinical-to-clinic pathway, with solid rationale, feasibility, and milestones.

Leverage existing resources (MJFF cohorts, consortia, shared datasets) or propose to build tools/data for the community.

Assemble a diverse, multidisciplinary team if possible — basic science, clinical, industry or translational experts.

Focus on patient value — improved therapy, better biomarkers, symptom control, or data to speed therapeutics.

Make your research open, collaborative, and sharable — data-sharing, consortium participation, resource sharing are plus points.

Use a lean, clearly justified budget, and ensure no overlap with other funding.

Ensure the PI is clearly defined, and institutional support/commitments are explicit.

Specialties

Neurosciences

Eligibility Requirements

MJFF will prioritize proposals that:

Demonstrate strong PD study volume, including interventional clinical trials, and readiness to support study referrals.

Establish well defined Access Advocate role with appropriate training and supervision.

Implement repeatable workflows for identifying potential participants, assessing barriers, connecting people to resources and follow-up.

Include a feasible plan to track recruitment, retention, and barrier related metrics and site-relevant health system outcomes.

Show Access Advocates' effect on recruiting and retaining underrepresented groups in PD studies.

Commit to participating in cross-site learnings to share insights and improve the Access Advocate model.

MJFF will NOT consider proposals from sites:

Outside of the US and Canada.

Without active or planned interventional PD clinical trials.

Proposing a model centered primarily on broad community outreach rather than clinic and trial connected access advocacy.

Sponsor Details

Sponsor Institute/Organizations: Fox (Michael J.) Foundation for Parkinson's Research

Sponsor Type: Corporate/Non-Profit

Address: P.O. Box 4777 New York, NY 10163-4777

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity